An observational study in Type1diabetes, sponsored by Institut de Recherches Cliniques de Montreal. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Institut de Recherches Cliniques de Montreal · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 705 studies in Motor Activity with a site in Canada — 135 open to participants now, 165 under way, 2 of them phase 3. Motor Activity · Canada.
Among the 705 studies in Motor Activity with a site in Canada, this one is the 15th largest by planned enrollment of the 42 observational ones that give a count, is one of 43 that started in 2022, is one of 42 observational ones, reaches primary completion later than 59 of the 164 other live ones, and was the 516th registered.
9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →135 of the 705 studies in Motor Activity with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
McMaster University · Sites in Canada
Ages 18–35 · Healthy volunteers
University of Ottawa · Sites in Canada
Ages 45–65 · Men only · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–79 · Healthy volunteers
University of Toronto · Sites in Canada
Ages 18–35 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
705 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 39 · Phase 3 20 · Phase 4 17
First in 1997; this study’s year is marked. 43 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is below the median of 98 across 1,240 observational studies indexed under Motor Activity.
Median enrollment 46 across the 661 interventional studies, 50 across the 42 observational. Of the 476 that completed or were terminated, 41 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 705 have an industry lead sponsor. The 10 most frequent:
Institut de Recherches Cliniques de Montreal is the lead sponsor of 61 studies on the registry; 11 are open to participants now.
Institut de Recherches Cliniques de Montreal has 8 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
43 of the studies in Motor Activity with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717710University of British ColumbiaIvabradine for Heart Rate Reduction During Exercise in Healthy Adults | 2026-12 |
| NCT04078334Université du Québec a MontréalPersonalized Exercises Program Prescription to Prevent Functional Decline Throughout Older Adults Hospitalization | 2026-12 |
| NCT04970888Montreal Heart InstituteComparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure | 2026-12-01 |
| NCT04426786Pacific Parkinson's Research CentreExercise & Brain Energetics in PD | 2026-12-30 |
| NCT07389837Université de MontréalMaple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance | 2026-12-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 705 studies in Motor Activity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In clinical practice, women living with type 1 diabetes frequently report that insulin requirements change across the menstrual cycle. Consequently, glycemic fluctuations are observed. This phenomenon could be explained by a decrease in insulin sensitivity during the second half of the menstrual cycle (luteal phase).
Overall, despite an important proportion of women reporting glycemic and/or insulin variations across the menstrual cycle, studies to date have involved small sample sizes, and have had inconsistent results. The objective of this study will be to study glycemic fluctuations across the menstrual cycle using CGM data, alongside insulin data, in a large sample of women.
Women aged 18 to 50 living with type 1 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Continuous glucose monitoring · Drug: Insulin · Other: Premenstrual symptoms · Other: Ovulation kits · Device: Fitbit Inspire 2 · Other: Keenoa · Other: Menstrual cycle
Glucose levels will be measured using continuous glucose monitoring
Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
Ovulation testing will be done using ovulation kits
Physical activity will be assessed using the Fitbit Inspire 2
Food intake will be assessed using the Keenoa phone application
The application My Calendar will be used to record information on the menstrual cycle
Mean glucose levels during the early follicular phase
Time frame: Day 1 to 5 of the menstrual cycle
Mean glucose levels during the mid-late follicular phase
Time frame: Day 6 until 2 days prior to ovulation
Mean glucose levels during the periovulation phase
Time frame: Ovulation plus/minus 1 day
Mean glucose levels during the early luteal phase
Time frame: Day 2 to 4 after ovulation
Mean glucose levels during the mid-luteal phase
Time frame: Day 5 to 9 after ovulation
Mean glucose levels during the late luteal phase
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels between 3.9 and 7.8 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels between 3.9 and 10.0 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels below 3.9 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels below 3.0 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels above 10.0 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Day 1 to 5 of the menstrual cycle
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Day 6 until 2 days prior to ovulation
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Ovulation plus/minus 1 day
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Day 2 to 4 after ovulation
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Day 5 to 9 after ovulation
Percentage of time of glucose levels above 13.9 mmol/L
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Standard deviation of glucose levels
Time frame: Day 1 to 5 of the menstrual cycle
Standard deviation of glucose levels
Time frame: Day 6 until 2 days prior to ovulation
Standard deviation of glucose levels
Time frame: Ovulation plus/minus 1 day
Standard deviation of glucose levels
Time frame: Day 2 to 4 after ovulation
Standard deviation of glucose levels
Time frame: Day 5 to 9 after ovulation
Standard deviation of glucose levels
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Coefficient of variance of glucose levels
Time frame: Day 1 to 5 of the menstrual cycle
Coefficient of variance of glucose levels
Time frame: Day 6 until 2 days prior to ovulation
Coefficient of variance of glucose levels
Time frame: Ovulation plus/minus 1 day
Coefficient of variance of glucose levels
Time frame: Day 2 to 4 after ovulation
Coefficient of variance of glucose levels
Time frame: Day 5 to 9 after ovulation
Coefficient of variance of glucose levels
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Low blood glucose index
Time frame: Day 1 to 5 of the menstrual cycle
Low blood glucose index
Time frame: Day 6 until 2 days prior to ovulation
Low blood glucose index
Time frame: Ovulation plus/minus 1 day
Low blood glucose index
Time frame: Day 2 to 4 after ovulation
Low blood glucose index
Time frame: Day 5 to 9 after ovulation
Low blood glucose index
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
High blood glucose index
Time frame: Day 1 to 5 of the menstrual cycle
High blood glucose index
Time frame: Day 6 until 2 days prior to ovulation
High blood glucose index
Time frame: Ovulation plus/minus 1 day
High blood glucose index
Time frame: Day 2 to 4 after ovulation
High blood glucose index
Time frame: Day 5 to 9 after ovulation
High blood glucose index
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Standard deviation of insulin delivery
Time frame: Day 1 to 5 of the menstrual cycle
Standard deviation of insulin delivery
Time frame: Day 6 until 2 days prior to ovulation
Standard deviation of insulin delivery
Time frame: Ovulation plus/minus 1 day
Standard deviation of insulin delivery
Time frame: Day 2 to 4 after ovulation
Standard deviation of insulin delivery
Time frame: Day 5 to 9 after ovulation
Standard deviation of insulin delivery
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Coefficient of variance of insulin delivery
Time frame: Day 1 to 5 of the menstrual cycle
Coefficient of variance of insulin delivery
Time frame: Day 6 until 2 days prior to ovulation
Coefficient of variance of insulin delivery
Time frame: Ovulation plus/minus 1 day
Coefficient of variance of insulin delivery
Time frame: Day 2 to 4 after ovulation
Coefficient of variance of insulin delivery
Time frame: Day 5 to 9 after ovulation
Coefficient of variance of insulin delivery
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Total insulin delivery
Time frame: Day 1 to 5 of the menstrual cycle
Total insulin delivery
Time frame: Day 6 until 2 days prior to ovulation
Total insulin delivery
Time frame: Ovulation plus/minus 1 day
Total insulin delivery
Time frame: Day 2 to 4 after ovulation
Total insulin delivery
Time frame: Day 5 to 9 after ovulation
Total insulin delivery
Time frame: Day 10 after ovulation until the first day of the next menstrual cycle
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Apr 2026, 46 months after the start.
Of 492 non-industry observational studies under Motor Activity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 46 months is above that.
Counting every sponsor, half of 502 studies reached it within 22 months; a quarter within 8 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recherches Cliniques de Montreal